We are pleased to welcome Dr. Andreas Lazaros Chryssafidis, DVM, DSc, to our Ireland facility staff. Dr. Chryssafidis has an extensive background in veterinary parasitology and the conduct of animal clinical trials, and brings more than 12 years of expertise to the Charles River team.
Renovations to the stability suites at our site in Malvern, PA, are now complete! The facility supports our comprehensive stability testing program and offers greater capabilities for the conduct of stability studies, from IND through BLA submission.
We have established a comprehensive in vivo model for the assessment of neuropathic pain treatment options. This rat model of spinal nerve ligation (SNL)-induced neuropathy has been validated with several antinociceptive agents. With this data, we have demonstrated the model’s reliability for testing treatment effects.
With the emergence of sensitive novel kidney injury markers, we are excited to announce the availability of multiplexed assays to analyze these biomarkers in the urine of rats and large animals.
Charles River is proud to announce that its research model breeding and services facilities in France, Germany and Italy have recently received accreditation of their animal care and use programs from AAALAC International. Only a handful of commercial breeders in Europe have received this prestigious accreditation.
In response to the increase in demand for high-quality New Zealand White (NZW) rabbits, Charles River has entered into a contract breeding partnership with Oakwood Research, Inc.
The direct peptide reactivity assay (DPRA) is a test that can be used to predict whether a chemical may be a skin sensitizer. It can replace or act as a screen for in vivo animal tests.
Charles River now offers pharmacokinetic (PK) and efficacy studies in swine. The swine housing at the Wilmington, MA, site has been expanded and new efficacy models are being established.
The maximum risk of human exposure to any agrochemical product arises during manufacture, equipment preparation and application of the product. Regulatory requirements state that the exposure risk to the individual should be properly assessed at each point in the production, preparation and application process so that appropriate protective equipment, handling and exclusion procedures can be recommended.
Robert “Sandy” Hodgson will apply his expertise in neuropharmacology to develop new and refine existing in vivo technologies used for the assessment of novel chemical entities and new transgenic models.